Ryan D Gentzler MD (He/Him)

Clinical Trials

• Lung-MAP: Biomarker-Targeted Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer Start of enrollment: 2014 Jul 08

  Completed

• Consolidation Pembrolizumab Following Chemoradiation in Patients With Inoperable/Unresectable Stage III NSCLC Start of enrollment: 2015 Mar 09

  Completed

  Phase 2

• Carboplatin/Nab-Paclitaxel and Pembrolizumab in NSCLC Start of enrollment: 2015 Jun 04

  Terminated

  Phase 1, Phase 2

• Osimertinib and Navitoclax in Treating Patients With EGFR-Positive Previously Treated Advanced or Metastatic Non-small Cell Lung Cancer Start of enrollment: 2016 Aug 30

  COMPLETED

  PHASE1

• Nivolumab After Surgery and Chemotherapy in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer (An ALCHEMIST Treatment Trial) Start of enrollment: 2016 Jul 22

  ACTIVE_NOT_RECRUITING

  PHASE3

• Lung-MAP: Taselisib as Therapy in Treating Patients With Stage IV Squamous Cell Lung Cancer and Positive Biomarker Matches Start of enrollment: 2014 Nov 01

  Completed

  Phase 2

• Lung-MAP: Palbociclib as Second-Line Therapy in Treating Cell Cycle Gene Alteration Positive Patients With Recurrent Stage IV Squamous Cell Lung Cancer Start of enrollment: 2014 Sep 01

  Completed

  Phase 2, Phase 3

• Lung-MAP: Nivolumab With or Without Ipilimumab as Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer and No Matching Biomarkers Start of enrollment: 2015 Dec 29

  Active, not recruiting

  Phase 3

• Durvalumab and Tremelimumab in Treating Patients With Recurrent Stage IV Lung Cancer Start of enrollment: 2017 Nov 30

  Completed

  Phase 2

• Rucaparib in Treating Patients With Genomic LOH High and/or Deleterious BRCA1/2 Mutation Stage IV or Recurrent Non-small Cell Lung Cancer (A Lung-MAP Treatment Trial) Start of enrollment: 2019 Apr 16

  ACTIVE_NOT_RECRUITING

  PHASE2

• Lung-MAP: A Master Screening Protocol for Previously-Treated Non-Small Cell Lung Cancer Start of enrollment: 2019 Feb 06

  RECRUITING

  PHASE2, PHASE3

• Real-Time Monitoring of Symptoms in Lung Cancer Patients Receiving Oral Targeted Therapies Start of enrollment: 2022 Aug 25

  Active, not recruiting

  Not Applicable

• Testing the Addition of an Anti-cancer Drug, Entinostat, to the Usual Chemotherapy and Immunotherapy Treatment (Atezolizumab, Carboplatin and Etoposide) for Previously Untreated Aggressive Lung Cancer That Has Spread Start of enrollment: 2021 Apr 27

  Completed

  Phase 1

• TAK-788 as First-Line Treatment Versus Platinum-Based Chemotherapy for Non-Small Cell Lung Cancer (NSCLC) With EGFR Exon 20 Insertion Mutations Start of enrollment: 2020 Jan 10

  ACTIVE_NOT_RECRUITING

  PHASE3

• Adagrasib + SRS for Patients With Metastatic KRAS G12C-mutated NSCLC With Untreated Brain Metastases Start of enrollment: 2024 Aug 06

  RECRUITING

  PHASE2

• MOnaliZumab in Combination with DurvAlumab (MEDI4736) Plus Platinum-based ChemotheRapy for First-line Treatment of Extensive Stage Small Cell Lung Cancer Start of enrollment: 2023 Sep 26

  RECRUITING

  PHASE2

• Ramucirumab Plus Pembrolizumab vs Usual Care for Treatment of Stage IV or Recurrent Non-Small Cell Lung Cancer Following Immunotherapy, Pragmatica-Lung Study Start of enrollment: 2023 Mar 14

  RECRUITING

  PHASE3

• A Global Study to Assess the Effects of Durvalumab With Oleclumab or Durvalumab With Monalizumab Following Concurrent Chemoradiation in Patients With Stage III Unresectable Non-Small Cell Lung Cancer Start of enrollment: 2022 Feb 07

  RECRUITING

  PHASE3

• A Study of Amivantamab and Lazertinib in Combination With Platinum-Based Chemotherapy Compared With Platinum-Based Chemotherapy in Patients With Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non- Small Cell Lung Cancer After Osimertinib Failure Start of enrollment: 2021 Nov 17

  ACTIVE_NOT_RECRUITING

  PHASE3

• Join now to see all